About ALS & the MND Spectrum — Context for PLS Patients

This page is not the focus of this site. You have PLS — or are trying to find out if you do — and ALS is what you are hoping to rule out. This page explains what ALS is, how it differs from PLS, what the "conversion" question actually involves, and why the two diseases exist in the same medical conversation at all. It is written as context, not as the main event.

Why read about ALS if you have PLS?

Because your doctor almost certainly mentioned it during your diagnosis process. Because every search you run for PLS returns pages about ALS alongside it. Because someone in your life has asked "isn't that like ALS?" and you want to be able to answer clearly. And because one question — "could this turn into ALS?" — is probably sitting somewhere in the back of your mind.

Understanding ALS in basic terms makes you a more informed patient. It helps you understand what your neurologist is watching for, why certain tests are repeated over time, and what "definite PLS" means when a doctor says you have it. It does not mean ALS is your story. For most people diagnosed with PLS, it is not.

What ALS is — a brief clinical overview

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that destroys motor neurons — the nerve cells that control voluntary muscle movement. Unlike PLS, which affects only one type of motor neuron, ALS destroys both:

Upper motor neurons (UMN) — originating in the motor cortex of the brain, projecting down through the corticospinal tracts to the spinal cord. Their loss causes spasticity, stiff muscles, and exaggerated reflexes.
Lower motor neurons (LMN) — sitting in the spinal cord and brainstem, relaying signals directly to muscles. Their loss causes muscle wasting, weakness, and fasciculations (the visible spontaneous twitching of muscle fibers).

The combination of both types of degeneration, in multiple body regions, is what makes ALS progress so rapidly and cause such profound disability. When lower motor neurons die, muscles lose their direct nerve supply. They waste visibly. They twitch. The double destruction — from above and below — is the defining pathology of ALS.

ALS is diagnosed when a combination of upper and lower motor neuron signs appears in more than one body region, without another explanation. The current diagnostic standard (the 2019 Gold Coast criteria) requires progressive motor weakness consistent with both UMN and LMN degeneration, supported by electrophysiological testing. No single test diagnoses ALS; it is a clinical diagnosis by exclusion and accumulation of evidence.

Approximately 5,000 new ALS cases arise in the United States each year. Worldwide prevalence is roughly 4–5 per 100,000 people. About 90–95% of cases are sporadic — no clear genetic cause. The most common ALS-associated genes include C9orf72, SOD1, and TDP-43.

Key differences from PLS: the things that actually matter

Progression speed

In ALS, functional decline is rapid. The ALSFRS-R (the standard functional rating scale) drops at approximately 5 or more points per year in typical ALS. Median survival from symptom onset is 2–5 years, with a median of about 3 years.

In PLS, decline is measured in years to decades. The ALSFRS-R drops at approximately 1.6–1.9 points per year on average — roughly three times slower than ALS. Median survival from symptom onset is approximately 23 years. Median age at death in PLS is 79.5 years, close to the general population reference of 81.9 years.

Life expectancy

This is the most important difference for someone navigating a possible diagnosis. In ALS, life expectancy is significantly shortened — respiratory failure is the typical cause of death. In PLS, life expectancy is anticipated to be near-normal. Only about 6% of PLS patients ever require non-invasive ventilation, and only 10% require a feeding tube. The disease causes significant disability — primarily mobility and spasticity — but not the respiratory crisis that defines ALS's prognosis.

Lower motor neuron involvement

The clinical distinction that defines both diseases: PLS affects only upper motor neurons. ALS affects both. Practically, this means that in PLS you will not develop the muscle wasting, visible fasciculations, or EMG findings of denervation that characterize ALS. If those signs appear, the diagnosis changes.

Cognitive changes

In ALS, cognitive and behavioral changes affect up to 50% of patients on sensitive testing, and approximately 15% develop full frontotemporal dementia (ALS-FTD). In PLS, significant cognitive impairment is uncommon — though neuroimaging does reveal some extra-motor changes in the frontotemporal and subcortical regions, suggesting the "pure upper motor neuron" picture is not the complete story.

The "spectrum" concept — MND as a continuum

Motor neuron disease (MND) is not a single condition. It is a spectrum of related disorders, all involving the progressive degeneration of motor neurons, but differing in which neurons are affected, how rapidly, and with what clinical features. The main positions on this spectrum:

Primary Lateral Sclerosis (PLS) — pure upper motor neuron degeneration. Slowest progression, near-normal life expectancy.
UMN-dominant ALS — predominantly upper motor neuron disease, with some lower motor neuron signs but less than typical ALS. Intermediate between PLS and classic ALS.
Typical (classic) ALS — both upper and lower motor neurons affected, in multiple regions. Most common MND. Rapid progression.
Progressive Muscular Atrophy (PMA) — predominantly lower motor neuron disease. Rare. Lower motor neuron signs without clear upper motor neuron involvement at onset.
Primary Bulbar Palsy — degeneration beginning in the bulbar region (speech, swallowing), usually progressing to typical ALS.

Where does PLS sit on this spectrum? Research — including molecular and genetic analyses — increasingly suggests that PLS may represent one end of a disease continuum rather than a wholly separate disease. Some scientists frame it as "UMN-predominant ALS." The clinical boundary between PLS and UMN-dominant ALS can be unclear, which is part of why the 2020 consensus diagnostic criteria were developed and why diagnosis takes time.

This framing does not mean PLS is ALS. It means the biology connects. For your daily life, the clinical difference — slower progression, near-normal life expectancy, no lower motor neuron loss — is what matters.

The 23% conversion question — what the data actually shows

Approximately 23% of people who initially present with a pure upper motor neuron syndrome will, over time, develop lower motor neuron signs — fasciculations, muscle wasting, EMG changes — and be reclassified as ALS. This is the conversion figure you may have encountered.

Several things are important to understand about this number:

It is front-loaded

Conversion to ALS almost always happens within the first four years of symptom onset. The 2020 PLS consensus criteria set the "definite PLS" threshold at four or more years of pure upper motor neuron symptoms for precisely this reason. After four years with no lower motor neuron signs, conversion becomes rare. The longer you have had pure UMN symptoms, the less likely conversion becomes.

What conversion means clinically

Conversion is not a sudden transformation. It means that lower motor neuron signs appear on examination or on EMG — things that were not present before. Clinically, your neurologist will watch for fasciculations (particularly in the tongue or hands), visible muscle atrophy, diminishing reflexes in a region where they were previously brisk, and EMG changes showing active denervation. If you develop any of these, your neurologist will reassess your diagnosis.

What the threshold of "definite PLS" means for you

If you have had pure upper motor neuron symptoms for four or more years without lower motor neuron signs appearing, your neurologist can apply the label "definite PLS." This is a meaningful clinical designation — not certainty in an absolute sense, but a strong evidence base. At that point, the probability of conversion is substantially reduced and the reassuring data on PLS prognosis applies to you with more confidence.

The "probable PLS" period

Between two and four years of pure UMN symptoms, the 2020 criteria classify the diagnosis as "probable PLS." This is the most uncertain period — not because ALS is likely, but because the clinical picture has not yet accumulated enough time to be definite. It is during this period that the conversion question feels most pressing. That is expected. It does not mean the outcome will be conversion; for most people in this window, it will not be.

Why ALS gets most of the research attention

If you have spent any time reading about motor neuron disease, you have noticed that ALS dominates the research literature, the clinical trial infrastructure, the advocacy organizations, and the public conversation. PLS is frequently an afterthought — or a footnote. There are reasons for this, and understanding them is useful.

ALS is significantly more common than PLS. It is estimated that PLS represents only 1–4% of all motor neuron disease cases. ALS affects approximately 30,000 Americans at any given time; PLS affects far fewer. Research funding tends to follow patient numbers.

ALS also has urgency that PLS does not. With a median survival of three years, an ALS diagnosis creates immediate pressure on researchers to develop interventions quickly. The humanitarian argument for prioritizing ALS research is straightforward. PLS, with its decades-long trajectory, does not create the same sense of emergency — even though the cumulative disability it causes is real and significant.

The consequence for PLS patients is that most of the clinical trial infrastructure, most of the drug pipelines, and most of the multidisciplinary care protocols were built around ALS and then adapted to PLS imperfectly. The PLS Natural History Study and the 2020 consensus criteria are beginning to change this — building the data infrastructure PLS needs to attract its own research attention. But the field is still catching up.

ALS drugs — brief reference for context

Four drugs have received FDA approval for ALS. None are approved or indicated for PLS, and a trial of riluzole in PLS did not show benefit. They are listed here for reference, because you will encounter them in reading about motor neuron disease:

Riluzole (Rilutek) — approved 1995. Reduces glutamate toxicity. Extends ALS survival by approximately three months. The first ALS drug. A trial in PLS did not demonstrate benefit.
Edaravone (Radicava) — approved 2017. An antioxidant. Slowed functional decline in a specific early-ALS patient subgroup in its pivotal trial.
Tofersen (Qalsody) — approved 2023. An antisense oligonucleotide targeting the SOD1 gene — the first gene-specific ALS therapy. Relevant only to the approximately 2% of ALS patients with a SOD1 mutation.
AMX0035 (Relyvrio) — approved 2022, subsequently withdrawn from the US market after a confirmatory trial failed to replicate the initial results. No longer commercially available in the US as of 2024.

The absence of disease-modifying drugs for PLS is not an oversight — it reflects the combination of small patient numbers, the long and slow disease course (which makes clinical trials difficult to design and interpret), and the late development of validated outcome measures for PLS. For the current state of PLS treatment, see treatments.

ALS caregiving — brief reality check

If you are caring for someone with ALS, rather than PLS, the experience is fundamentally different from what this site describes for PLS caregiving. ALS caregiving is intensive, time-compressed, and medically complex in ways that PLS caregiving typically is not.

In advanced ALS, caregivers commonly provide 50–80 hours of care per week — an amount exceeding a full-time job. The care includes respiratory support (BiPAP, eventually ventilators), nutrition support (feeding tubes), secretion management, transfers, communication devices, and around-the-clock monitoring. This is a different order of intensity than PLS caregiving, which more closely resembles long-term support for a chronic mobility condition than care for a terminal illness.

The ALS Association and I AM ALS provide extensive caregiver resources designed for this context. The resources on this site are designed for PLS caregivers and may not fully address what ALS caregiving involves. See the ALS organizations listed below.

Resources specifically for ALS

If someone you know has an ALS diagnosis — or if you are navigating a period of diagnostic uncertainty — the following organizations have extensive, ALS-specific resources:

ALS Association (als.org) — the primary US advocacy organization. Chapter network, care services, clinical trial finder, caregiver resources, equipment lending.
I AM ALS (iamALS.org) — patient-founded advocacy and community organization. Peer support networks, policy advocacy, caregiver communities.
Northeast ALS Consortium (NEALS) (neals.org) — consortium of ALS research centers. Trial finder and information about consortium-sponsored research.
Healey ALS Platform Trial (massgeneral.org/als) — the major ALS platform trial at Massachusetts General Hospital.
MND Association (UK) (mndassociation.org) — UK's leading MND organization, with resources relevant to both ALS and PLS.
Target ALS (targetals.org) — research foundation focused on accelerating ALS drug development.